A rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma with multiple solitary extramedullary plasmacytomas of the liver
-
- OHARA Fumiya
- Department of Hematology, Toyota Kosei Hospital
-
- HARADA Yasuhiko
- Department of Hematology, Toyota Kosei Hospital
-
- TANIKAWA Yoshimasa
- Department of Respiratory Medicine, Toyota Kosei Hospital
-
- NARITA Michihiko
- Department of Pathology, Toyota Kosei Hospital
-
- KAGAMI Yoshitoyo
- Department of Hematology, Toyota Kosei Hospital
-
- HIRAGA Junji
- Department of Hematology, Toyota Kosei Hospital
Bibliographic Information
- Other Title
-
- 肝に多発性髄外形質細胞腫が診断された多発性骨髄腫と肺がんの同時性重複がん
- カン ニ タハツセイズイガイケイシツ サイボウ シュ ガ シンダン サレタ タハツセイ コツズイシュ ト ハイ ガン ノ ドウジセイ チョウフク ガン
Search this article
Description
<p>We report the case of a 62-year-old woman with multiple liver tumors. She was diagnosed with synchronous occurrence of multiple myeloma (MM) and primary pulmonary adenocarcinoma 4 years ago. She was treated with bortezomib and dexamethasone for MM, and then she underwent thoracoscopic lobectomy. After the surgery, she received autologous peripheral blood stem cell transplantation. However, recurrence of MM was observed 9 months later. She received multiple chemotherapies for MM, but the effect was limited. Meanwhile, brain metastasis of pulmonary adenocarcinoma was observed; therefore, she underwent surgical resection and received radiation therapy. Furthermore, she had elevated levels of liver enzymes, and ultrasonography revealed multiple liver tumors. Because of thrombocytopenia, liver biopsy could not be performed, and chemotherapies for MM did not improve the tumors. Therefore, we clinically determined that the liver tumors were metastatic pulmonary adenocarcinomas. The epidermal growth factor receptor mutation was present in the pulmonary adenocarcinoma, so gefitinib was administered. However, the tumors were uncontrollable and the patient died within 1 month. From autopsy, the liver lesion was confirmed to be MM. Synchronous occurrence of MM and other primary cancers is very rare, and no standard treatment has yet been established. Thus, it is crucial to accumulate synchronous cases and develop treatment methods in the future.</p>
Journal
-
- Rinsho Ketsueki
-
Rinsho Ketsueki 62 (7), 727-732, 2021
The Japanese Society of Hematology
- Tweet
Details 詳細情報について
-
- CRID
- 1390851883593743232
-
- NII Article ID
- 130008071868
-
- NII Book ID
- AN00252940
-
- ISSN
- 18820824
- 04851439
-
- NDL BIB ID
- 031639403
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL
- CiNii Articles
- Crossref
-
- Abstract License Flag
- Disallowed